This could be explained by the fact, that GFAP seems to be a marker of the earliest AD pathology with an association between GFAP levels and amyloid load, while NfL could be more useful in terms of disease monitoring and progression (Verberk et al., 2021; Ebenau et al., 2022). This evidence concerns the gene NEFL and Alzheimer disease.